The COVID-19 pandemic had many pharmas turning to DCTs as a way to keep the clinical wheel turning. Can the industry keep that flexibility going forward?
The post-COVID outlook for decentralized clinical trials
top of page
Search
bottom of page
The COVID-19 pandemic had many pharmas turning to DCTs as a way to keep the clinical wheel turning. Can the industry keep that flexibility going forward?